Abequolixron (RGX-104)是一种具有口服活性的liver X receptor激动剂，可通过转录激活ApoE基因调节内源性免疫反应。 Information RGX-104 RGX-104 is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene. Targets LXR In vitro RGX-104 is an oral first-in-class LXR agonist that robustly induces ApoE expression resulting in innate-immune mediated anti-tumor activity. RGX-104 drives anti-tumor immunity by regulating the abundance and activity of myeloid derived suppressor cells (MDSC) and dendritic cells (DC). In vivo Antitumor activity has been demonstrated with RGX-104 monotherapy in several syngeneic and xenograft tumor models, including melanoma, lung cancer, ovarian cancer, GBM and others. The anti-tumor activity of LXR-agonism is related to constitutive upregulation of ApoE expression.
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
RGX-104
CAS number：610318-03-1 molecular formula：C34H34Cl2F3NO3
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | AMY16847 | MS-30867 | SB-742881 HYDROCHLORIDE | BENZENEACETIC ACID, 3-((3R)-3-(((2-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)METHYL)(2,2-DIPHENYLETHYL)AMINO)BUTOXY)-, HYDROCHLORIDE (1:1) | BCP29451 | UNII-D32013XLTX | AC-31569 | RGX104 HCl | RGX-104 HCl | (3-((3R) | ||
| CAS number | 610318-03-1 | molecular formula | C34H34Cl2F3NO3 |
| molecular weight | 632.54 g/mol | Exact mass | 10mM in DMSO |
| PSA | 49.800 Ų | logp | 5.85 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
